CD82/Pax7-positive target populations might have translational potential for CRISPR/Cas9-mediated editing in the context of muscular dystrophies, insofar as HDR in differentiated skeletal muscle remains challenging. The gene discussed is CD82; the disease is muscular dystrophy.